指南与共识前列腺癌

主动监测时代前列腺局灶治疗的患者选择:一项国际德尔菲共识项目

Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project.
指南 / 共识 · Prostate Cancer Prostatic Dis · 2017-03-28

该国际德尔菲共识项目由47名前列腺局灶治疗(FT)专家经三轮在线问卷和一轮面对面会议,就活检/影像、疾病和患者因素三领域达成共识;18个亚领域中16个达成共识,认为mpMRI是FT患者选择的标准影像工具,D'Amico低/中危含Gleason 4+3可推荐FT,Gleason 3+4局限且大小有利为理想病例。

要点

  • mpMRI是FT患者选择的标准影像工具,可疑病灶须组织学确认后行FT。
  • 系统活检仍用于评估mpMRI阴性区域,但充分标准尚未确定。
  • D'Amico低/中危含Gleason 4+3可推荐FT;Gleason 3+4局限、离散且大小有利为理想病例。

核心结论

  • 该共识提供了当前专家对临床局限前列腺癌FT患者选择的意见。

研究设计与样本

  • 四阶段德尔菲共识项目,由47名国际前列腺FT专家参与,经三轮迭代在线问卷和反馈收集三个主要领域数据。
  • 共识定义为≥80%医师同意,最后由16名核心专家参加面对面会议审查数据并制定共识声明。

主要发现

  • 18个亚领域中16个达成共识。
  • mpMRI是FT患者选择的标准影像工具;存在mpMRI可疑病灶时FT前须组织学确认;系统活检仍用于评估mpMRI阴性区域,但充分标准尚未确定。
  • D'Amico低/中危癌包括Gleason 4+3可推荐FT;Gleason 3+4癌局限、离散且大小有利代表FT理想病例。
  • 肿瘤灶<1.5 ml(mpMRI)或<20%前列腺适合FT;若局限于一侧半腺则可达3 ml或25%;未治疗区域一个穿刺针1 mm的Gleason 3+3可接受。
  • 保留性功能是重要目标,但勃起功能缺乏不应将患者排除在FT之外。

关键数值与推荐

  • 共识定义为≥80%医师同意。
  • D'Amico低/中危癌包括Gleason 4+3可推荐FT。
  • Gleason 3+4癌局限、离散且大小有利为FT理想病例。
  • 肿瘤灶<1.5 ml(mpMRI)或<20%前列腺适合FT;局限于一侧半腺则可达3 ml或25%。
  • 未治疗区域一个穿刺针1 mm的Gleason 3+3可接受。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whole-gland extirpation or irradiation is considered the gold standard for curative oncological treatment for localized prostate cancer, but is often associated with sexual and urinary impairment that adversely affects quality of life. This has led to increased interest in developing therapies with effective cancer control but less morbidity. We aimed to provide details of physician consensus on patient selection for prostate focal therapy (FT) in the era of contemporary prostate cancer management. METHODS: We undertook a four-stage Delphi consensus project among a panel of 47 international experts in prostate FT. Data on three main domains (role of biopsy/imaging, disease and patient factors) were collected in three iterative rounds of online questionnaires and feedback. Consensus was defined as agreement in ⩾80% of physicians. Finally, an in-person meeting was attended by a core group of 16 experts to review the data and formulate the consensus statement. RESULTS: Consensus was obtained in 16 of 18 subdomains. Multiparametric magnetic resonance imaging (mpMRI) is a standard imaging tool for patient selection for FT. In the presence of an mpMRI-suspicious lesion, histological confirmation is necessary prior to FT. In addition, systematic biopsy remains necessary to assess mpMRI-negative areas. However, adequate criteria for systematic biopsy remains indeterminate. FT can be recommended in D'Amico low-/intermediate-risk cancer including Gleason 4+3. Gleason 3+4 cancer, where localized, discrete and of favorable size represents the ideal case for FT. Tumor foci <1.5 ml on mpMRI or <20% of the prostate are suitable for FT, or up to 3 ml or 25% if localized to one hemi-gland. Gleason 3+3 at one core 1mm is acceptable in the untreated area. Preservation of sexual function is an important goal, but lack of erectile function should not exclude a patient from FT. CONCLUSIONS: This consensus provides a contemporary insight into expert opinion of patient selection for FT of clinically localized prostate cancer.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Tay KJ, Scheltema MJ, Ahmed HU, et al. Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project. Prostate Cancer Prostatic Dis. 2017. PMID: 28349978. doi:10.1038/pcan.2017.8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。